Larimar Therapeutics (LRMR): Rentabilitas dodolan miturut bathi resik

Larimar Therapeutics Inc (LRMR) - logo korporat

Larimar Therapeutics (LRMR) is developing exclusive therapies for rare brain pathologies, ensuring significant pricing power upon commercialization. Currently, the business is burning capital on research without generating real revenue or stable cash flow. The nearest catalysts are linked to the approval of a drug for Friedreich's ataxia. The net operating margin helps assess profitability, where the 0.00 indicator determines the magnitude of the metric.

Margin resik Larimar Corp (LRMR): kanggo periode 04.07.2022 - 19.11.2026

Larimar Pharma (LRMR) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Analisis kabeh metrik perusahaan:Larimar Therapeutics
Produk asil prodhuksi Larimar Therapeutics Inc

Environmental synthesis optimization and rigorous safety controls at Larimar Therapeutics (LRMR) establish the foundation for operational resilience, which is reflected in the aggregate net margin on the GURU.Markets platform. This indicator measures the portion of profit from every dollar of revenue after deducting all expenses, allowing investors to determine the fair value of shares and avoid overpaying for the asset by analyzing efficiency extremes.